Neuroblastoma Maintenance Therapy Trial
Active, not recruiting · Phase 2 · NCT02679144
Conditions: Neuroblastoma
At a glance
- Research payments reported, 2025
- $32,600
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 441
About the trial
- Sponsor
- Giselle Sholler (with Beat NB Cancer Foundation, Team Parker for Life)
- Tested
- Difluoromethylornithine (DFMO) (drug)
- Dates
- Started 2016-02; completion 2033-02
- Results posted
- Not yet
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
From ClinicalTrials.gov, last updated 2026-09-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Uswm, LLC reported $32,600 in research payments for this study in 2025 (6 payments).
Products named: Iwilfin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Pennsylvania State University $20,350
- $12,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.